Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/6/2008

,570 $7,393,722

Acquired in-process R&D $- $29,481,894

Net loss $(22,411,121) $(49,889,057)

Dividend on Series A convertible

preferred stock $(1,005,000) $(1,005,000)

Net loss attributable to common

shareholders $(23,416,121) $(50,894,057)

Net loss per share attributable to

common shareholders (basic and diluted) $(0.28) $(0.71)

Weighted average number of

shares outstanding (basic and diluted) 84,166,552 71,873,734

Cash and Short-term Investments $47,748,191 $50,570,097


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chroni
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
...hows naturally occurring antibodies contained in, ...for Alzheimer,s disease, CHICAGO, April 15 The U...axter International Inc. (NYSE: BAX ) today,annou...tural antibodies,contained in GAMMAGARD LIQUID [Im... as KIOVIG in the European Union, a plasma-derived...
.../PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(...sentation by Dr.,Chandini Thirukkumaran of the Tom... Multiple Myeloma with Oncolytic Viral Therapy" wa...Cancer Research (AACR) Annual,Meeting. The meeting...,12-16, 2008., The presentation covered preclinic...
... CryoPort, Inc. (OTC,Bulletin Board: CYRX) (http...ent,community through their personal profile on My...he dynamic profile will include interviews with co...ent, and links to recent press., Visit CryoPort,.../profile.php?ID=19849 . Stay updated about CryoPo...
Other Biology Technology:Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting 2CryoPort Creates Personal Wall on Wallst.net's Financial Social Community, my.wallst.net 2
(Date:12/4/2009)UVALDE Dr. Daniel Leskovar, a Texas AgriLife Research plant physiologist at the Texas AgriLife Research and Extension Center in Uvalde, has been investigating ways to help vegetable plants make a les
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How to read brain activity? 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court Ordered Meeting of Shareholders 50160 1Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court Ordered Meeting of Shareholders 50160 2Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 50156 1Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 50156 2Immucor Responds To FDA Notice 12802 1Immucor Responds To FDA Notice 12802 2
... signs of spring, like budding trees, are worth ce...mergence of fertile, winged termites swarming furi... them. , In New Orleans, as the swirling, airborn...archers with the Agricultural Research Service (AR...omeday knock down large numbers of Formosan subter...
...r imaging technologies allow physicians to visuali...tecting small blood clots not previously seen, but...,s outcome, a new study suggests. , The study incl...m. About half of the patients (98) had a multidete...gle-detector CT examination. The radiology examina...
...School of Medicine scientists have created the fir... possibly prevent the onset of a brain disease in ...indings, published online this week in the journal...velopment of a vaccine to prevent a group of fatal...cles called prions. , Although no cure for these d...
Other Biology News:Fungus Effective Against Winged Termites 2Newer imaging techniques may lead to over-treatment 2Active Vaccine Prevents Mice From Developing Prion Disease 2Active Vaccine Prevents Mice From Developing Prion Disease 3
GIBCO Dulbecco's Phosphate-Buffered Saline (D-PBS) (1X) liquid from Invitrogen
Rabbit Anti-LSD1 / BHC110 Antibody, Unconjugated from Upstate
Dulbecco's Phosphate-Buffered Saline (D-PBS) powder from Invitrogen
Rabbit Anti-CUGBP2 Monoclonal Antibody, Unconjugated, Clone PADZMD.495 from Invitrogen
Biology Products: